On August 17, 2026, the Company announced the appointment of Markus Loeffler, MD, MBA, as Chief Medical Officer. Dr. Loeffler brings over 30 years of experience in oncology drug development and will oversee the clinical advancement of the Company’s pipeline. On June 30, 2026, the Company announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations. Both appointees bring over 30 years of experience in their respective fields, strengthening the Company’s legal, governance, and clinical development capabilities. On February 24, 2026, the Company announced the presentation of data from its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference. The presentation, delivered by Dr. Jonathan Davis, Director of ADC Discovery, highlighted the therapeutic potential of CEACAM6 across multiple epithelial cancers and preclinical data demonstrating the tumor-selective binding profile of the Company’s proprietary anti-CEACAM6 VHH (nanobody). On February 5, 2026, the Company announced the extension of its Research and Exclusive Option Agreement with metaShape Pharma AG covering LEUMUNA™ for adipose tissue-related and metabolic diseases through December 31, 2028. Under the agreement, metaShape is developing the compound, designated MS 001, as an oral co-therapy for GLP-1 receptor agonists, with preclinical data demonstrating improved weight loss outcomes and reduced weight regain following GLP-1 withdrawal. The extension preserves the Company’s strategic optionality in metabolic indications while allowing it to maintain its primary focus on the oncology applications of the compound. On August 13, 2025, the Company announced the publication of a peer-reviewed article by Frontiers in Oncology reporting results from a previously completed Phase I/II clinical study of L-DOS47 as a single agent in patients with advanced non-small cell lung cancer (NSCLC) and titled “Safety of unconventional antibody-drug conjugate L-DOS47 in a Phase I/II monotherapy study targeting advanced NSCLC”. On August 8, 2025, the Company received positive and constructive feedback in writing from the US Food and Drug Administration (FDA) on the study design of LDOS007, ahead of a planned End-of-Phase-I (EOPI) meeting that was scheduled with the FDA via videoconference on August 13. 2025. LDOS007 is a new Phase Ib/Randomized Phase II, open label study to assess L-DOS47 in combination with pembrolizumab as first-line therapy in NSCLC, currently in the planning stage. As the FDA indicated that the Company could proceed without the meeting if the written feedback was sufficiently clear, and given that no additional discussion was deemed necessary, the Company elected to forego the videoconference in favor of preparing the Clinical Trial Application (CTA) as the next step in its interactions with the Agency.
On September 28, 2026, the Company announced the appointments of Karen Krumeich, Jamieson Bondarenko, CFA, CMT, Charmaine Lykins, MBA, and Dirk Brockstedt, PhD, to its Board of Directors, with Ms. Krumeich assuming the role of Chair. The Company also announced the resignations of Jacek Antas, Malgorzata Laube, and Jerzy Leszczynski. Following these changes, the Board comprises six directors, five of whom are independent. The Company also reconstituted its Audit Committee, comprising three independent directors: Karen Krumeich as Chair, Zachary T. Stadnyk, and Jamieson Bondarenko. On August 14, 2026, the Company announced the resignation of Janusz Grabski from its Board of Directors and the appointment of Chief Executive Officer (CEO) Thomas Mehrling, MD, PhD, as a director. On June 12, 2026, the Company announced the filing of its unaudited interim financial statements for the three- and nine-month periods ended April 30, 2026, together with the related Management’s Discussion and Analysis (MD&A) and CEO and CFO certifications. The filings were made available on SEDAR+ and the Company’s website. On May 27, 2026, the Company issued unsecured convertible debentures with aggregate principal of $3,673,000. The debentures bear simple interest at 25% per annum, mature on July 27, 2027, and are convertible at the holder’s option on maturity, with principal convertible at $1.42 per Common Share. On May 22, 2026, the Company announced the grant of 1,297,000 incentive stock options at an exercise price of $1.63 per Common Share, expiring May 21, 2031. The Company also announced the cancellation of 2,200,000 previously granted stock options held by a director, exercisable at $1.10 per common share, resulting in a net reduction of 903,000 outstanding stock options. On May 13, 2026, the Company announced the appointment of Zachary T. Stadnyk, former Head of Life Sciences at the TSX and TSXV, to its Board of Directors, and Natalia L. Butterworth, an experienced corporate governance professional, as Corporate Secretary. The Company also announced plans to relocate its registered and records office from Toronto to Vancouver, British Columbia. On March 16, 2026, the Company announced the filing of its unaudited interim financial statements for the three- and six-month periods ended January 31, 2026, together with the related MD&A and CEO and CFO certifications. The filings were made available on SEDAR+ and the Company’s website. On January 30, 2026, the Company announced the voting results of its Annual General and Special Meeting of Shareholders, at which all resolutions were approved with over 99.99% of votes cast in favor, including the re-election of four directors, the appointment of Clearhouse LLP as auditor, and a proposed share consolidation at a ratio of up to five pre-consolidation common shares for one post-consolidation common share, with the final ratio to be determined by the Board of Directors. A total of 61,885,815 common shares were voted, representing 81.03% of the Company’s issued and outstanding shares. On December 15, 2025, the Company announced the filing of its unaudited interim financial statements for the three-month period ended October 31, 2025, together with the related MD&A and CEO and CFO certifications. The filings were made available on SEDAR+ and the Company’s website. On December 3, 2025, the Company entered into a subscription agreement for a proposed $33,370,000 equity financing. The subscriber subsequently declared bankruptcy and, consequently, the financing did not close. On October 29, 2025, the Company announced its financial results for the fiscal year ended July 31, 2025, reporting a net loss of $5,205,000 ($0.09 per share), compared with $9,264,000 ($ 0.21 per share) in fiscal 2024. On October 6, 2025, the Company issued a statement in response to recent market activity, announcing that it was not aware of any material undisclosed information that would account for the increase in the market price and trading volume of its common shares. On September 9, 2025, the Company announced its participation in the Q3 2025 Investor Summit Virtual on September 16–17, 2025, where CEO Thomas Mehrling, MD, PhD, would present the Company’s ongoing preparations for LDOS007. On September 5, 2025, the Company announced it will not proceed with the previously announced equity draw-down subscription facility with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited (together, “GEM”), given that the Company determined that the GEM facility no longer aligns with its capital strategy or its commitment to maximizing long-term shareholder value. On August 22, 2025, the Company closed its non-brokered private placement of 2,222,333 common shares of the Company at a price of $0.75 per Common Share for gross proceeds of $1,667,000.